- HDSA Names 56 Centers of Excellence and 11 Partner Sites in 2023
- HDSA Research Webinar NEXT WEEK! Novartis Discusses the VIBRANT-HD Trial
- GENERATION HD2 underway: What do we know so far?
HDSA Names 56 Centers of Excellence and 11 Partner Sites in 2023
This week, HDSA announced its Center of Excellence network will grow in 2023! HDSA named one new Center of Excellence and one new partner site for a total of 56 HDSA COEs and 11 regional partner sites. These 56 grants total $2,029,759 of support for expert HD care at 67 distinct medical facilities in 36 states across the nation and Washington, DC.
Professionals at these locations include neurologists, psychiatrists, social workers, therapists, and counselors with extensive HD experience who work together to provide care and support for HD families. Because HDSA is highly committed to supporting clinical research, HDSA Centers of Excellence are not only important for delivering specialty medical care to HD families, they are also key for connecting families with opportunities to participate in HD research. We’re excited to continue the expansion of expert HD research and care nationwide with the growth of this network.
HDSA Research Webinar NEXT WEEK! Novartis Discusses the VIBRANT-HD Trial
Join HDSA at 12 PM Eastern Time on Wednesday, February 22nd for a Research Webinar in which clinical leaders and Novartis representatives will talk about the VIBRANT-HD trial and the decision to stop development of branaplam in HD. There will be a live community Q&A to follow. Speakers will include VIBRANT-HD clinical site investigator and chair of the trial Steering Committee Dr. Blair Leavitt, from the UBC Centre for Huntington Disease; Novartis Medical lead for the branaplam program, Dr. Harry Ramos, and Novartis Clinical program head for the branaplam program, Dr. Beth Borowsky. To register, click here.
GENERATION HD2 underway: What do we know so far?
Last week, HDSA hosted Drs. Lauren Boak and Peter McColgan for a research webinar covering Roche’s new Phase II study of tominersen, GENERATION HD2. The webinar covered questions from the community as well as the goals of the new study, how this trial is different from GENERATION HD1, who is eligible to enroll, and more. To watch the full webinar, click here.
This week, HDBuzz delivered a recap of what we know about the tominersen program so far. This run-down covers the bigger picture of huntingtin-lowering for HD, how the Phase III study of tominersen, GENERATION HD1, led to this new trial, the goals of GENERATION HD2, and more. To read the full article, click here.